HC Wainwright & Co. maintains Alumis at Buy, lowers price target to $9 from $15
HC Wainwright & Co. kept its Buy rating on Alumis but reduced its price target from $15 to $9, a 40% drop. This implies a 46.8% upside from the Nov 12 close of $6.13.
How this was made
The 30-second read
Why it matters
The target reduction reduces the perceived upside, likely prompting short‑term selling pressure.
Market read
Analyst downgrade for a micro‑cap may cause modest price decline; limited broader market effect.
What to watch
No new product or regulatory news; the downgrade is purely opinion‑based.
Background
Alumis is a micro‑cap biotech company; analyst coverage can significantly affect its price.
Market effects
Minimal impact on the broader biotech sector.
Limited to US micro‑cap investors.
Low
Counterpoint
Some investors may view the cut as an overreaction and see buying opportunity.
Key entities
- AnalystHC Wainwright & Co.
Equity research firm issuing the rating change.
- CompanyAlumis
Biotech firm subject of the rating change.
